Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Adv Drug Saf. 2013 Aug 1;4(4):155-169.

Pharmacogenetic testing: Current Evidence of Clinical Utility.

Author information

  • 1Duke Institute for Genome Sciences & Policy 304 Research Drive Box 90141 Durham, NC 27708 USA jivan.moaddeb@duke.edu.

Abstract

Over the last decade, the number of clinical pharmacogenetic tests has steadily increased as understanding of the role of genes in drug response has grown. However, uptake of these tests has been slow, due in large part to the lack of robust evidence demonstrating clinical utility. We review the evidence behind four pharmacogenetic tests and discuss the barriers and facilitators to uptake: 1) warfarin (drug safety and efficacy); 2) clopidogrel (drug efficacy); 3) codeine (drug efficacy); and 4) abacavir (drug safety). Future efforts should be directed toward addressing these issues and considering additional approaches to generating evidence basis to support clinical use of pharmacogenetic tests.

PMID:
24020014
[PubMed]
PMCID:
PMC3765014
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1.
Figure 2.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk